Belmont Village Senior Living's Allyson Fujii Honored with CALA Excellence in Service Award
HOUSTON--(BUSINESS WIRE)--Belmont Village Senior Living, a leading developer, owner, and operator of senior living communities across the nation, proudly announces that Allyson Fujii, Director of Memory Programs at Belmont Village San Jose, has received the California Assisted Living Association (CALA) Excellence in Service Award. The prestigious honor, awarded during the 2025 CALA Spring Conference, celebrates Allyson's exceptional contributions to memory care programming and her deep commitment to improving residents' lives.
Since starting her career at Belmont Village in 2013 as an Enrichment Leader, leading activities for residents with cognitive impairment, Allyson has grown into her role as the Memory Programs Director, where she has taken full ownership over the care, programming, and experiences of residents in the Memory Care enrichment programs. Her innovative approach, compassion, and leadership have transformed the memory care experience for residents, families, and staff alike, and her devotion to the residents extends to everyone at Belmont Village San Jose. Allyson's programming not only enhances cognitive engagement but also supports residents in expressing themselves, fostering connections, and maintaining a sense of purpose.
'Allyson is a true changemaker in our community,' said Executive Director of Belmont Village San Jose, Rachel Brown. 'Her energy, creativity, and dedication are unmatched. She has created an environment where residents feel seen, heard, and empowered, and where staff feel inspired to give their best.'
Known for her warmth and collaboration, Allyson builds strong relationships with families and leads with a deep sense of empathy. Allyson prioritizes getting to know residents and their families on a personal level to create customized, meaningful moments for each resident. She has developed programs that embrace residents' individuality while guiding team members with a strong, supportive presence. Her passion for innovation has helped implement successful, person-centered memory care practices that continue to evolve and grow under her leadership.
'We are so proud of Allyson and her career thus far at Belmont Village,' said Mercedes Kerr, President of Belmont Village Senior Living. 'Her commitment to excellence and tireless dedication to our mission have impacted countless lives. For over a decade, she has seized the growth opportunities Belmont Village proudly creates, realizing her amazing leadership potential. We are grateful for her contribution and the way she helps to share who we are as a company. We are thrilled that CALA has recognized her with this well-deserved honor.'
Allyson is one of five Belmont Village team members to receive a CALA Excellence in Service Award since 2023, which reflects the organization's commitment to excellence in senior care and its investment in cultivating exceptional talent across its communities. This growing recognition underscores Belmont Village's culture of support, innovation, and leadership development at every level of the organization.
About Belmont Village Senior Living
Founded in Houston in 1997, Belmont Village is an integrated developer, owner, and operator of high-quality senior living communities, with more than 4,600 employees and 5,000 units in total. Its 35 locations across the country and in Mexico City, provide award-winning assisted living and memory care programs and ongoing collaborations with Baptist Health South Florida, UC San Diego, USC, UCLA, UC Berkeley, and more to continually improve their cognitive health and evidence-based enrichment programs. The company is a market leader in major markets including South Florida, the San Francisco Bay Area, Los Angeles, San Diego, and Chicago. Renowned for distinctive design, high standards of life and safety, and reputation for leading edge, quality programming, Belmont Village has been certified as a Great Place to Work ® since 2018, has been ranked as one of FORTUNE Magazine's 50 Best Workplaces for Aging Services for five years, and has been recognized by U.S News & World Report as Best in Senior Living. www.belmontvillage.com, LinkedIn, Facebook, Instagram.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
3 days ago
- Business Wire
Belmont Village Senior Living's Allyson Fujii Honored with CALA Excellence in Service Award
HOUSTON--(BUSINESS WIRE)--Belmont Village Senior Living, a leading developer, owner, and operator of senior living communities across the nation, proudly announces that Allyson Fujii, Director of Memory Programs at Belmont Village San Jose, has received the California Assisted Living Association (CALA) Excellence in Service Award. The prestigious honor, awarded during the 2025 CALA Spring Conference, celebrates Allyson's exceptional contributions to memory care programming and her deep commitment to improving residents' lives. Since starting her career at Belmont Village in 2013 as an Enrichment Leader, leading activities for residents with cognitive impairment, Allyson has grown into her role as the Memory Programs Director, where she has taken full ownership over the care, programming, and experiences of residents in the Memory Care enrichment programs. Her innovative approach, compassion, and leadership have transformed the memory care experience for residents, families, and staff alike, and her devotion to the residents extends to everyone at Belmont Village San Jose. Allyson's programming not only enhances cognitive engagement but also supports residents in expressing themselves, fostering connections, and maintaining a sense of purpose. 'Allyson is a true changemaker in our community,' said Executive Director of Belmont Village San Jose, Rachel Brown. 'Her energy, creativity, and dedication are unmatched. She has created an environment where residents feel seen, heard, and empowered, and where staff feel inspired to give their best.' Known for her warmth and collaboration, Allyson builds strong relationships with families and leads with a deep sense of empathy. Allyson prioritizes getting to know residents and their families on a personal level to create customized, meaningful moments for each resident. She has developed programs that embrace residents' individuality while guiding team members with a strong, supportive presence. Her passion for innovation has helped implement successful, person-centered memory care practices that continue to evolve and grow under her leadership. 'We are so proud of Allyson and her career thus far at Belmont Village,' said Mercedes Kerr, President of Belmont Village Senior Living. 'Her commitment to excellence and tireless dedication to our mission have impacted countless lives. For over a decade, she has seized the growth opportunities Belmont Village proudly creates, realizing her amazing leadership potential. We are grateful for her contribution and the way she helps to share who we are as a company. We are thrilled that CALA has recognized her with this well-deserved honor.' Allyson is one of five Belmont Village team members to receive a CALA Excellence in Service Award since 2023, which reflects the organization's commitment to excellence in senior care and its investment in cultivating exceptional talent across its communities. This growing recognition underscores Belmont Village's culture of support, innovation, and leadership development at every level of the organization. About Belmont Village Senior Living Founded in Houston in 1997, Belmont Village is an integrated developer, owner, and operator of high-quality senior living communities, with more than 4,600 employees and 5,000 units in total. Its 35 locations across the country and in Mexico City, provide award-winning assisted living and memory care programs and ongoing collaborations with Baptist Health South Florida, UC San Diego, USC, UCLA, UC Berkeley, and more to continually improve their cognitive health and evidence-based enrichment programs. The company is a market leader in major markets including South Florida, the San Francisco Bay Area, Los Angeles, San Diego, and Chicago. Renowned for distinctive design, high standards of life and safety, and reputation for leading edge, quality programming, Belmont Village has been certified as a Great Place to Work ® since 2018, has been ranked as one of FORTUNE Magazine's 50 Best Workplaces for Aging Services for five years, and has been recognized by U.S News & World Report as Best in Senior Living. LinkedIn, Facebook, Instagram.
Yahoo
27-05-2025
- Yahoo
Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise
SAN DIEGO, May 27, 2025--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise. In this role Allyson will be joining Acadia's commercial leadership team with a focus on maximizing the potential of DAYBUE® and preparing for future product launches as the Company expands its rare disease portfolio. "We are delighted to welcome Allyson to Acadia," said Catherine Owen Adams, Chief Executive Officer. "She brings a remarkable breadth of experience across U.S. and global sales and marketing roles, with a proven track record of delivering strong commercial results. Her leadership across therapeutic areas—including oncology, immunology, CNS, infectious disease, cardiovascular and metabolic disorders—as well as her experience specifically in rare oncology, will be invaluable as we grow the DAYBUE brand and advance our pipeline to bring new therapies to patients in need." Allyson's distinguished career spans more than 20 years in the global pharmaceutical industry including various sales positions, both in primary care and specialty sectors, at Pfizer, and significant commercial roles at Bristol Myers Squibb (BMS). Most recently, Allyson served as Senior Vice President and Business Unit Head, U.S. Oncology at BMS, where she provided strategic oversight for two major acquisitions in rare tumors, resulting in successful product launches and significant market share growth. Beyond her operational expertise, Allyson is recognized as a driven and highly capable leader who fosters an inclusive culture that embraces both strategic and solution-oriented innovation. "I am excited to join Acadia Pharmaceuticals," said Allyson McMillan-Youngblood. "Acadia has a strong commitment to patient care and innovation, and I look forward to working with the team to drive DAYBUE growth and prepare to bring new therapies to patients with rare diseases." Allyson holds a Bachelor of Science in Business Administration from Florida A&M University. She has been consistently recognized for her ability to lead through change and her commitment to improving patient outcomes throughout her career. About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson's disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer's disease psychosis and multiple other programs targeting neuroscience and neuro-rare diseases. For more information, visit us at and follow us on LinkedIn and X. View source version on Contacts Investor Contact: Acadia Pharmaceuticals Kildani(858) 261-2872ir@ Acadia Pharmaceuticals Tieszen(858) 261-2950ir@ Media Contact: Acadia Pharmaceuticals Kazenelson(818) 395-3043media@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
27-05-2025
- Business Wire
Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise. In this role Allyson will be joining Acadia's commercial leadership team with a focus on maximizing the potential of DAYBUE ® and preparing for future product launches as the Company expands its rare disease portfolio. 'We are delighted to welcome Allyson to Acadia,' said Catherine Owen Adams, Chief Executive Officer. 'She brings a remarkable breadth of experience across U.S. and global sales and marketing roles, with a proven track record of delivering strong commercial results. Her leadership across therapeutic areas—including oncology, immunology, CNS, infectious disease, cardiovascular and metabolic disorders—as well as her experience specifically in rare oncology, will be invaluable as we grow the DAYBUE brand and advance our pipeline to bring new therapies to patients in need.' Allyson's distinguished career spans more than 20 years in the global pharmaceutical industry including various sales positions, both in primary care and specialty sectors, at Pfizer, and significant commercial roles at Bristol Myers Squibb (BMS). Most recently, Allyson served as Senior Vice President and Business Unit Head, U.S. Oncology at BMS, where she provided strategic oversight for two major acquisitions in rare tumors, resulting in successful product launches and significant market share growth. Beyond her operational expertise, Allyson is recognized as a driven and highly capable leader who fosters an inclusive culture that embraces both strategic and solution-oriented innovation. 'I am excited to join Acadia Pharmaceuticals,' said Allyson McMillan-Youngblood. 'Acadia has a strong commitment to patient care and innovation, and I look forward to working with the team to drive DAYBUE growth and prepare to bring new therapies to patients with rare diseases.' Allyson holds a Bachelor of Science in Business Administration from Florida A&M University. She has been consistently recognized for her ability to lead through change and her commitment to improving patient outcomes throughout her career. About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson's disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer's disease psychosis and multiple other programs targeting neuroscience and neuro-rare diseases. For more information, visit us at and follow us on LinkedIn and X.
